Nové možnosti aplikace sekukinumabu (studie ALLURE a MATURE)
| Title in English | New options for secukinumab application (ALLURE and MATURE studies) |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Keywords | psoriasis – secukinumab – application device – ALLURE and MATURE trial |
| Description | Treatment options for severe plaque psoriasis continue to expand, and with new biological preparations, emphasis is placed not only on efficacy and safety, but also on the highest possible level of comfort for patients during this treatment. The benefits of the new application form of secukinumab secukinumab (a pre-filled syringe containing 300 mg of secukinumab in 2 ml and a pre-filled pen UnoREADY 300 mg) were investigated in the ALLURE and MATURE studies. Both of the above-mentioned studies have shown that both new application forms have at least the same effectiveness as the previous application forms, they do not carry any new undesired safety signals and their tolerability is excellent. In addition, by reducing the number of necessary drug applications by half, they significantly increase the comfort of patients when applying this therapy (especially the pre-filled Cosentyx UnoREADY pen), and thus also their overall satisfaction and adherence to treatment. |